New cancer combo aims to rev up immune system against tumors
NCT ID NCT05651022
First seen Jan 17, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This early-stage trial tests a new drug called Decoy20, which is designed to activate the immune system to fight cancer. It is being tested alone or with another drug, tislelizumab, in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are to check safety, find the right dose, and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Gabrail Cancer & Research Center
Canton, Ohio, 44718, United States
-
Hoag Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Prisma Health Cancer Institute-ITOR
Greenville, South Carolina, 29605, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
UH Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Southern California- Norris Cancer Center
Los Angeles, California, 90033, United States
-
Washington University, Siteman Cancer Center
St Louis, Missouri, 63108, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Decoy20 (a cancer immunotherapy that activates the immune system) and tislelizumab (a drug that helps immune cells attack cancer)
What this could lead to
If it works, this could point toward a new treatment option for several advanced cancers, including liver, lung, and colorectal cancers.
What could go wrong
This is an early phase 1/2 trial with only 120 participants, so it's mainly checking safety and dosing. The treatment may not shrink tumors or could cause side effects like immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.